No recent analyst price targets found for SLXN.
Latest News for SLXN
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLXN.
U.S. House Trading
No House trades found for SLXN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.